AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-MEDICAL LABORATORIES
NeuroSense Therapeutics Ltd. Ordinary Shares
XNAS · usd
SIC 8071 · SERVICES-MEDICAL LABORATORIES
FIGI BBG0132WLC45
2.46▲ 0.02 (0.82%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.44
Day's Range
2.40 – 2.55
52-Week Range
0.25 – 7.50
Volume
11.1K
Avg Volume
23.1K
Share Statistics
Shares Outstanding
Employees
16
Exchange
XNAS
Listed
2021-12-09
Share count as of June 30, 2026

NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)
What is NeuroSense Therapeutics Ltd. Ordinary Shares's Market Cap?
NeuroSense Therapeutics Ltd. Ordinary Shares's Market Cap is $4.5M, based on as-reported figures from SEC (XBRL) filings.
What is NeuroSense Therapeutics Ltd. Ordinary Shares's Enterprise Value?
NeuroSense Therapeutics Ltd. Ordinary Shares's Enterprise Value is $4.4M, based on as-reported figures from SEC (XBRL) filings.
What is NeuroSense Therapeutics Ltd. Ordinary Shares's EV / EBITDA?
NeuroSense Therapeutics Ltd. Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is NeuroSense Therapeutics Ltd. Ordinary Shares's Net Income (TTM)?
NeuroSense Therapeutics Ltd. Ordinary Shares's Net Income (TTM) is -$11.1M, based on as-reported figures from SEC (XBRL) filings.
What is NeuroSense Therapeutics Ltd. Ordinary Shares's EBITDA?
NeuroSense Therapeutics Ltd. Ordinary Shares's EBITDA is -$11.1M, based on as-reported figures from SEC (XBRL) filings.
What is NeuroSense Therapeutics Ltd. Ordinary Shares's Diluted EPS (TTM)?
NeuroSense Therapeutics Ltd. Ordinary Shares's Diluted EPS (TTM) is -6.06, based on as-reported figures from SEC (XBRL) filings.
What is NeuroSense Therapeutics Ltd. Ordinary Shares's Net Debt?
NeuroSense Therapeutics Ltd. Ordinary Shares's Net Debt is -$166.0K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NRSNAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Research and development expenses
General and administrative expenses
Operating loss
Financing expenses, net
Net loss and comprehensive loss
Basic net loss per share (in Dollars per share)
Diluted net loss per share (in Dollars per share)